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I
n the UK, there is a growing policy for non-medical 
clinicians, such as allied health professionals and 
nurses, to undertake roles that were previously 
considered the remit of the medical profession. 
Examples include prescribing and procedures 
such as bronchoscopy, gastroscopy, and percutaneous 
epigastric feeding tube insertion.
Physical management and therapy are key 
components of spasticity management, and allied 
health professionals such as physiotherapists and 
occupational therapists are usually closely involved 
in the provision of treatment. The UK national 
guidelines for spasticity management recommend 
that treatment should be undertaken by an integrated 
Spasticity management with botulinum 
toxin: A comparison of UK physiotherapy 
and rehabilitation medicine injectors 
Abstract
Background/Aims: To compare patient outcomes following botulinum toxin (BoNT) injection by either 
physiotherapy or rehabilitation medicine (medical) professionals over a 3-year period.
Methods: A retrospective, observational cohort study was conducted in a specialised rehabilitation 
service providing spasticity management including BoNT injection and physical therapy (group therapy, 
individual therapy, self-exercise, and physical management programmes). Individualised goals were 
established prior to treatment using goal attainment scaling (GAS) by the multidisciplinary team. The 
Arm Activity measure (ArmA) was used to evaluate upper limb function and the Modified Ashworth 
Scale (MAS) used to evaluate spasticity.
Findings: A total of 262 patients were injected. Mean GAS T-score after treatment for the group was 
50.2 ± 6.7. GAS T-score for physiotherapy injectors (n=214 (82% of participants)) was 50.2 ± 6.4 and 
for rehabilitation medicine injectors (n=48 (18%)) 50.3 ± 7.9. No significant differences were identified in 
terms of goal achievement, upper limb passive function, or spasticity reduction between physiotherapy 
and rehabilitation medicine injectors. Differences were identified at both baseline (physiotherapist mean 
49.7; rehabilitation medicine mean 46.6) and follow-up for active function (physiotherapist mean 49.7; 
rehabilitation medicine mean 47.8) (ArmA active function subscale; p=0.03). No reportable adverse 
effects were recorded. No difference in the complexity of injection (e.g. complex clinical presentation, 
anticoagulation, or technical difficulty) between the injector groups was identified.
Conclusions: Clinical outcomes were comparable between physiotherapy and rehabilitation medicine 
injectors. No difference in side effect profile or complexity of injection was identified. In this cohort, 
injection of BoNT by a physiotherapist was as effective in terms of GAS as that undertaken by a 
rehabilitation medicine physician.
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■ Muscle spasticity ■ Supplementary prescribing
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multidisciplinary team (Royal College of Physicians, 
2018). The multidisciplinary model of working has led 
to different members of the team undertaking a broader 
range of procedures and the clinical responsibility 
for their delivery. In other areas of physiotherapy 
practice, benefit to patient care has been identified by 
non-medical staff assuming roles that were previously 
undertaken by medical colleagues (Daker-White et 
al, 1999).
There is now substantial literature demonstrating that 
botulinum toxin type A (BoNT) is a safe and effective 
treatment for spasticity in adults, demonstrating 
improvement across a wide range of goal areas 
(Bhakta et al, 2000; Brashear et al, 2004; McCrory et 
al, 2009; Shaw et al, 2010; Turner-Stokes et al, 2010; 
Ashford et al, 2015). In the UK, as a result of practice 
development and changes in the scope of practice for 
some professions, administration of BoNT can be 
undertaken by any appropriately skilled and trained 
clinician. Non-medical clinicians who administer 
BoNT without prescribing can administer a standard 
written prescription (Patient Specific Direction), or a 
Patient Group Direction. Patient Specific Directions 
are written instructions from an independent prescriber 
for a medicine to be supplied and administered, to a 
named patient, by an appropriately qualified health 
professional. Patient Group Directions are formal 
documents drawn up by an NHS Trust, providing 
written instruction for the supply and/or administration 
of a named medicine, by a named registered health 
professional, in a defined clinical situation, to a group 
of patients who may not have been individually 
identified before presenting for treatment.
Physiotherapists are among the non-medical 
clinicians who can also now train to prescribe and 
administer medications. Independent prescribers 
are specified health professionals (including 
physiotherapists) defined in law as being able to 
prescribe medicines independently. To be able to 
prescribe, the physiotherapist must be listed on the 
relevant regulatory register and annotated on that 
register as an independent prescriber, following 
successful completion of an approved training 
programme. Supplementary prescribing is also possible 
for physiotherapists and is a voluntary prescribing 
partnership between an independent prescriber 
(usually, though not exclusively, a physician) and the 
supplementary prescriber, to implement an agreed, 
patient-specific, clinical management plan (CMP). A 
CMP can include licensed, ‘off-label’, and unlicensed 
medicines. Supplementary prescribers are specified 
health professionals who have also undertaken the 
approved training. By implementing these prescribing 
rights, physiotherapists can prescribe as well as inject 
BoNT in clinical practice.
Despite these advances in clinical practice and 
policy, the Summaries of Product Characteristics 
(SPCs) for the three BoNT products commercially 
available in the UK (onabotulinumtoxinA, 
abobotulinumtoxinA, and incobotulinumtoxinA) 
indicate that administration under the licence is by 
a physician rather than any qualified clinician, as is 
currently allowed under UK law. There is a need for 
manufacturers to update their SPCs to account for 
developments in practice and prescribing in the UK. 
It is, however, important to determine whether there 
is a difference in outcomes and complication rates 
between medical and non-medical (in the case of this 
study, physiotherapist) injectors.
This preliminary study aimed to compare patient 
outcomes following BoNT injection by physiotherapy 
and rehabilitation medicine practitioners over a 
follow-up of just over 3 years (December 2011 to 
January 2015). We hypothesised that, as rehabilitation 
and injection practice in specialist services should 
be the same irrespective of who administers the 
injection, no difference would be seen in outcomes 
post-intervention between the two injector disciplines.
METHODS
Study design
This was a retrospective, observational cohort study 
using routinely collected clinical data, conducted 
in patients who received BoNT (Dysport®; 
abobotulinumtoxinA) for spasticity management 
intervention. All participants had a neurological 
condition with resultant problematic spasticity.
Setting
The study was  conducted in a specialised neurological 
rehabilitation service, providing inpatient, outreach, 
and outpatient spasticity management for patients 
with complex needs and, often, more severe spasticity.
Interventions
All participants were undergoing spasticity 
management, including BoNT injection and physical 
therapy (group therapy, individual therapy, self-
exercise, and/or physical management programmes 
incorporating input from care and nursing staff). All 
received BoNT injection and treatment planning with 
a physiotherapy or rehabilitation medicine injector and 
the multidisciplinary team.
‘In the UK, as a result of practice development and 
changes in the scope of practice for some professions, 
administration of BoNT can be undertaken by any 
appropriately skilled and trained clinician.’
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Medical and physiotherapy injectors had received 
formal and practice-based training in injection of BoNT 
and associated procedures (e.g. use of electromyogram 
for injection). They had also received training in goal-
setting (including goal-setting facilitation, negotiation, 
and application of  goal attainment scaling (GAS)) 
with patients, carers, and the multidisciplinary team, 
to both clearly identify and then evaluate the aims and 
outcomes of treatment. Both medical and physiotherapy 
injectors had over 6 years’ experience of injection of 
BoNT and associated procedures at the start of the study 
period, as well as advanced knowledge of the wider 
aspects of spasticity management and rehabilitation. All 
injectors were independent prescribers as of 2014, when 
independent prescribing by physiotherapists became 
possible in the UK. Prior to 2014, administration 
by a physiotherapist was either by supplementary 
prescribing or a Patient Group Direction.
Routine data collection was undertaken prospectively 
as part of an integrated care pathway (ICP) for focal 
spasticity management in this service. The ICP includes 
routine recording of the outcome measures used in 
this study. Injections were performed, as clinically 
appropriate, under electromyogram guidance and/or 
electrical stimulation. Comparison of outcomes was 
undertaken between those patients receiving injections 
from a physiotherapist and those receiving them from 
a rehabilitation medicine physician.
Outcome measures
Individualised goals were established prior to treatment, 
using GAS. In addition, the Arm Activity measure 
(ArmA) was used to evaluate upper limb function, 
and the Modified Ashworth Scale (MAS) to evaluate 
spasticity. A consistent measure of leg function was not 
routinely applied during the period of this retrospective 
study (the Leg Activity measure is now routinely 
used for this purpose). In some individual patients, 
10-metre, 6-metre, and 6-minute timed walks were 
applied, but these data could not be reported for the 
group as a whole.
The method used for GAS was as described by 
Turner-Stokes (2009a), based on the original method 
of Kiresuk and Sherman (1968). In summary, goals 
are identified to suit the individual and agreed by 
both the patient (or their carer, if the patient is unable 
to participate) and the treating team prior to starting 
treatment. Tightly defined goal definitions are drawn 
up to be ‘SMART’ (specific, measurable, achievable, 
realistic, and timed). Expected (predicted) levels of 
performance are scored on a 5-point scale ranging from 
–2 to +2. A score of 0 reflects achievement of the goal 
as expected, positive scores indicating achievement at 
higher levels, and negative scores at lower levels than 
expected. Multiple goals can be combined using a 
standard formula to derive a T-score reflecting overall 
achievement of the predicted outcome. If all goals are 
achieved as predicted, a GAS T-score of 50 will result 
(scale range 0–100).
The ArmA is a patient- or carer-rated, 20-item 
measure of difficulty in passive and active arm function. 
It comprises a seven-item passive function subscale 
and a 13-item active function subscale, and uses a 
Likert scoring system between 0 (no difficulty) and 
4 (unable to do task). The passive function subscale 
scores range from 0 to 28, and the active function 
subscale scores from 0 to 52. The ArmA has been 
systematically developed (Ashford and Turner-Stokes, 
2013; Ashford et al, 2013a), supporting content validity. 
It has then been psychometrically tested (Ashford 
et al, 2013b), providing initial support for construct 
validity, internal consistency, dimensionality, test–retest 
reliability, feasibility, and responsiveness. The MAS is 
a clinical measure of spasticity that is widely used in 
clinical practice and research (Wade, 1992; Brashear 
et al, 2002).
Significant complications or side effects, if 
occurring, were to be reported using the standard 
clinical adverse event reporting system in the UK.
Analysis
Descriptive analysis of the study participants, including 
diagnostic category and primary general functional 
deficits, was completed. Evaluation of overall change 
in the group was evaluated post-treatment using the 
Wilcoxon signed-rank test. Comparison of outcomes 
between medical and physiotherapy injectors was 
undertaken using the Mann–Whitney U test. The 
primary outcome measure was GAS, with secondary 
outcomes of ArmA and MAS.
Goal and muscle classifications were undertaken by 
two investigators independently and then compared, 
with agreement on the final categorisation reached. 
The option for a third reviewer to assess areas of 
disagreement was available, but not required.
Ethical permission to use clinical data for the 
purposes of research and evaluation was provided by 
the NRES Committee—Harrow (ref 04/Q0405/47).
RESULTS
A total of 262 patients received BoNT injections. 
‘Despite these advances in clinical practice and 
policy, the Summaries of Product Characteristics 
indicate that administration under the licence is by 
a physician rather than any qualified clinician, as is 
currently allowed under UK law.’
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The mean age of the participants was 53.6 ± 18.6 
years, 128 (49%) were male, and 134 (51%) were 
female. All patients had a neurological condition, 
with a diagnostic category of either acquired brain 
injury (n=233), progressive condition (n=25), spinal 
cord injury (n=3), or missing (n=1), and resultant 
clinical spasticity. Patient demographics are presented 
in Table 1.
No significant side-effects or complications 
requiring reporting were recorded within the study 
period. Of the 262 patients receiving BoNT, 214 (82%) 
received injection by a physiotherapist and 48 (18%) 
by a rehabilitation medicine physician. The range and 
frequency of muscles injected by physiotherapy and 
medical injectors are provided in Table 2.
Injection by physiotherapists was undertaken in 28 
individual muscles or muscle groups, while injection 
by rehabilitation medicine physicians was undertaken 
in 21 muscle groups. A total of 516 muscles in 214 
patients (mean 2.4 muscles per patient) were injected 
by a physiotherapist, while medical physicians injected 
a total of 141 muscles in 48 patients (mean 2.9 muscles 
per patient). Despite the difference in the overall 
number of injections, a similar proportion of muscles 
were injected per body region (upper limb, lower limb, 
and head and neck).
Goal and GAS outcome evaluation data were 
available for 112 patients injected by a physiotherapist 
and 28 patients injected by a rehabilitation medicine 
physician. Goal categories were compared between 
physiotherapy and medical injectors, and are presented 
in Table 3.
Some differences can be seen in the individual goals 
set and achieved between disciplines. Prevention of 
deterioration in range of movement was set as a goal 
in 12% of cases for physiotherapy, and in 44% of cases 
for rehabilitation medicine. Passive function goals were 
set in 56% of the physiotherapy group, and in 26% 
of the rehabilitation medicine group. Active function 
goals were set in 10% of cases with physiotherapy 
and 4% with rehabilitation medicine.
The GAS, ArmA, and MAS scales are ordinal in 
nature; therefore, non-parametric descriptive statistics 
are presented. However, data were normally distributed; 
therefore, parametric means are used, as commonly 
reported with GAS data in other studies. Mean GAS 
(T-score) for the total group at follow-up was 50.2 
± 6.7. GAS T-score and ArmA and MAS scores at 
baseline are presented in Table 4.
A significant change in GAS T-score was identified 
between pre- and post-intervention overall. A 
Wilcoxon signed-rank test showed a significant 
difference between pre and post-intervention 
scores (Z= -10.458, p=0.005). Median GAS score 
pre-intervention was 37.6 and post-intervention was 
50.0. Mean GAS T-score at follow-up was 50.2 ± 6.4 
in the physiotherapist group and 50.3 ± 7.9 in the 
rehabilitation medicine group.
No significant differences (Mann–Whitney U 
test) were identified for goal achievement (GAS 
T-score; p=0.48), upper limb passive function (ArmA 
passive function subscale; p=0.66), or spasticity 
reduction (MAS; p=0.29) between physiotherapy 
and rehabilitation medicine injectors. A difference 
was identified at both baseline and follow-up for 
active function (ArmA active function subscale; 
p=0.03). Table 4 shows the mean baseline scores 
and Table 5 shows the mean outcome scores. No 
significant differences were identified between 
groups at baseline for any other measures. Table 5 
presents the comparison of physiotherapy and 
rehabilitation medicine injectors in terms of the 
outcome measures applied.
No significant difference in the complexity of 
injection (e.g. complex clinical presentation or 
technical difficulty) could be identified between the 
injector groups, based on the database recording form 
and clinical protocol.
Table 1. Diagnosis and impairments of participants (n=262)  
by injector discipline
Physiotherapy 
(n=214)
Rehabilitation 
medicine (n=48)
Diagnosis
Acquired brain injury 190 (89%) 43 (90%)
   Stroke 74 25 
  Traumatic 102 16 
  Other 14 2 
Progressive 20 (9%) 5 (10%)
Spinal cord injury 3 (2%) 0
Missing 1 (0%) 0
Global impairment presentation
Physical 35 (16%) 21 (43%)
Physical/cognitive 20 (9%) 5 (10%)
Physical/communication 34 (16%) 8 (18%)
Physical/cognitive/communication 125 (59%) 14 (29%)
Paresis presentation
Hemiplegia 98 (46%) 30 (63%)
Monoplegia 4 (2%) 1 (2%)
Paraplegia 9 (4%) 1 (2%)
Tetraplegia 102 (48%) 16 (33%)
Missing 1 (0%) 0
Percentages are per profession (physiotherapy and rehabilitation medicine) and 
section (diagnosis, global impairment presentation, and paresis presentation)
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Table 2. Muscles injected by injector discipline (n=262)
Muscle Physiotherapy 
(n=214)
Rehabilitation medicine 
(n=48)
Upper limb
Infraspinatus 2 (0.5%) 0
Pectorals (major and minor) 19 (4%) 5 (3%)
Brachialis 47 (9%) 6 (4%)
Brachioradialis  36 (7%) 11 (8%)
Biceps brachii 46 (9%) 12 (9%)
Flexor carpi ulnaris 8 (2%) 4 (3%)
Flexor carpi radialis 4 (1%) 6 (4%)
Flexor digitorum superficialis 69 (13%) 22 (15%)
Flexor digitorum profundus 64 (12%) 11 (8%)
Flexor policis brevis 1 (0.5%) 0
Flexor policis longus 12 (2%) 4 (3%)
Pronator teres 1 (0.5%) 8 (6%)
Lumbricals 0 3 (2%)
Subtotal: upper limb 309 (60%) 92 (65%)
Lower limb
Hamstring muscle group (medial and lateral) 68 (14%) 12 (9%)
Adductor magnus and medius 29 (6%) 6 (4%)
Gastrocnemius 22 (4%) 11 (8%)
Soleus 22 (4%) 9 (6%)
Tibialis anterior 10 (2%) 1 (1%)
Tibialis posterior 6 (1%) 3 (2%)
Flexor digitorum longus 7 (1%) 0
Flexor halucis longus 2 (0.5%) 0
Extensor halucis longus 2 (0.5%) 1 (1%)
Quadriceps 5 (1%) 1 (1%)
Subtotal: lower limb 173 (34 %) 44 (31%)
Head, neck, and trunk
Trapezius 7 (1%) 0
Sternomastoid 10 (2%) 0
Masseter 8 (2%) 3 (2%)
Latissimus dorsi 6 (1%) 0
Temporalis 0 2 (1%)
Teres minor 1 (0.5%) 0
Scalene 2 (0.5%) 0
Sub-total: Head, neck, and trunk 34 (6%) 5 (4%)
Total muscles injected 516 141
Percentages are per profession (physiotherapy and rehabilitation medicine)
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Table 3. Proportion of goals set and achieved in the different goal areas by injector discipline
Goal domain Goal area Physiotherapy 
(n=112)
Rehabilitation medicine 
(n=28)
Number of 
goals set
Number 
of goals 
achieved
Number of 
goals set
Number 
of goals 
achieved
Symptoms and 
impairment
Pain 35 (17%) 33 (16%) 7 (15%) 5 (12%)
Involuntary movements 1 (0%) 1 (0%) 1 (2%) 0
Range of movement 
(prevention)
25 (12%) 22 (11%) 20 (44%) 16 (35%)
 Activities Passive function 116 (56%) 110 (53%) 12 (26%) 10 (22%)
Active function 21 (10%) 19 (9%) 2 (4%) 2 (4%)
Mobility 2 (1%) 2 (1%) 0 0
Other 9 (4%) 9 (4%) 4 (9%) 4 (9%)
Total* 209 (100%) 196 (94%) 46 (100%) 37 (82%)
*A mean of 1.9 goals per patient for the physiotherapy group and 1.6 goals per patient in the rehabilitation medicine group
Table 4. Goal attainment scaling, Arm Activity measure and Modified Ashworth Scale scores at baseline 
by injector discipline
Measure Physiotherapy (n=112) Rehabilitation medicine (n=28)
Mean (SD) Median (IQR) Mean (SD) Median (IQR)
GAS (T-score) 36.8 (3.6) 37.6 (0.1) 35.6 (4.5) 37.6 (6.1)
ArmA passive function 14.4 (5.6) 15.0 (9.0) 15.5 (6.6) 15.5 (10.5)
ArmA active function 49.4 (7.6) 52.0 (2.0) 46.6 (12.7) 51.0 (5.5)
MAS 2.9 (0.9) 3.0 (0.0) 2.6 (0.8) 3.0 (1.0)
ArmA: Arm Activity measure; GAS: goal attainment scaling; MAS: Modified Ashworth Scale; IQR: interquartile range; 
SD: standard deviation
Table 5. Goal attainment scaling, Arm Activity measure and Modified Ashworth Scale 
scores at 3 years’ follow-up by injector discipline
Measure Physiotherapy (n=112) Rehabilitation medicine (n=28)
Mean (SD) Median (IQR) Mean (SD) Median (IQR)
GAS (T-score) 50.2 (6.4) 50.0 (0.0) 50.3 (7.9) 50.0 (1.5)
ArmA passive function 10.2 (4.2) 10.0 (6.0) 9.8 (2.9) 9.00 (1.75)
ArmA active function 49.7 (5.8) 52.0 (2.0) 47.8 (4.5) 48.0 (9.75)
MAS 1.2 (0.5) 1.0 (1.0) 1.4 (0.6) 1.0 (1.0)
ArmA: Arm Activity measure; GAS: goal attainment scaling; MAS: Modified Ashworth Scale; SD: standard deviation;    
IQR: interquartile range
DISCUSSION
This study identifies comparable clinical outcomes 
between physiotherapy and rehabilitation medicine 
injectors providing spasticity intervention in this 
specialised rehabilitation service. It is of note that 
82% of injections were carried out by a physiotherapist. 
These findings are important in the context of 
increasing BoNT administration by physiotherapists 
and recent developments for independent prescribing 
in the profession.
International Journal of Therapy and Rehabilitation, Month 2018, Vol 25, No 00 7
©
 2
01
8 
M
A
 H
ea
lth
ca
re
 L
td
RESEARCH
No significant side effects or complications 
requiring formal reporting were recorded within the 
study period and, therefore, there was no identifiable 
difference by injector profession. A difference in 
the range of muscles injected by physiotherapy and 
rehabilitation medicine injectors was identified, 
with injection undertaken by physiotherapists in 28 
individual muscles or muscle groups, while injection 
was undertaken by rehabilitation medicine physicians 
in 21 muscle groups. No significant difference in the 
complexity of injection could be identified between 
the groups. The anticoagulation status of patients was 
not automatically entered into the database (normally 
being reported in the patient’s clinical notes), and 
therefore is not reported in the results; however, there 
was no indication of a difference between professions 
in the clinical protocol. It is, therefore, likely that the 
smaller range of muscles injected by a rehabilitation 
medicine physician is a function of the smaller number 
of injections undertaken in total by this profession.
In this cohort, injection of BoNT by a 
physiotherapist was as effective as injection undertaken 
by a rehabilitation medicine physician. The general 
rehabilitation and anatomical skills would be expected 
to be comparable across professions. The specific 
clinical skills for injection and administration of 
BoNT, including use of aids to examination such 
as electromyogram, also seemed comparable based 
on the clinical outcomes achieved. Physiotherapists 
should have an advantage in the expertise required 
for the designing of physical rehabilitation (given 
core professional expertise) and the management 
plans required alongside BoNT injection. Conversely, 
rehabilitation medicine injectors may have advantages 
in management of patients with complex medication 
regimens (again, given core professional expertise), 
which can impact on spasticity management.
Differences were identified between physiotherapy 
and rehabilitation medicine injectors in the categories 
of goals set and the rates of achievement in goal areas. 
However, a slightly greater proportion of injections 
was carried out for leg spasticity by physiotherapy 
injectors than rehabilitation medicine injectors, with 
the converse in the arm, which may account for 
much of this difference. Some genuine differences 
may be present, with the physiotherapists setting 
slightly more functional goals than the rehabilitation 
medicine physicians, but it is not possible to draw firm 
conclusions from the current study.
The approach used for spasticity management 
in these patients was consistent with recommended 
practice (Royal College of Physicians, 2018). 
Multidisciplinary goal and treatment planning was 
undertaken in all cases. Goal-setting using GAS 
was applied, specifically related to focal spasticity 
management with BoNT. Patient engagement and 
satisfaction with goal-setting were not explicitly 
measured or evaluated in this cohort; however, in 
common with described practice (Turner-Stokes et 
al, 2015), patients and carers (where appropriate) 
were fully engaged in the process and, in particular, 
directing and evaluating the key aims of treatment. 
Goal negotiation was nevertheless undertaken to agree 
goals with the treating team.
In general, management of focal spasticity 
with BoNT injection is supported by guideline 
recommendations (Royal College of Physicians, 
2016; 2018), clinical trials (McCrory et al, 2009; 
Shaw et al, 2010; Turner-Stokes et al, 2010), and 
cohort study findings (Turner-Stokes, 2009b). In 
most cases, it is envisaged that it will be necessary 
to make further recommendations about physical 
management (or removal of provocative factors for 
spasticity) prior to pharmacological interventions or 
in combination with them. This study, in addition 
to demonstrating no difference in outcome between 
injector professions, again illustrates the benefits of 
coordinated interdisciplinary working in spasticity 
management, encompassing elements of physical 
management and supplemented by pharmacological 
interventions, in improving clinical outcomes and 
achieving patient-centred goals.
Limitations
The current study has some important limitations 
that need to be addressed in future work. Firstly, the 
study was conducted in one service offering spasticity 
management. The service is a specialised, regional 
service covering a large geographical area with a range 
of patients and spasticity severity. The service integrates 
the expertise of specialist allied health professionals 
and rehabilitation medicine physicians. Many of the 
patients seen have complex presentations and severe 
spasticity, which is likely to be reflected in the range 
of injections applied in this study group and may not 
translate exactly to other services. Working practices 
may also differ from other types of service.
Secondly, these data were routinely collected and, 
therefore, outcome evaluation was conducted with 
patients and carers by the same clinicians as those 
providing treatment. This may introduce possible 
‘This study, in addition to demonstrating no difference 
in outcome between injector professions, illustrates 
the benefits of coordinated interdisciplinary working 
in spasticity management, encompassing elements 
of physical management and supplemented by 
pharmacological interventions, in improving clinical 
outcomes and achieving patient-centred goals.’
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bias to the outcome evaluation, but this did not 
differ between physiotherapy and rehabilitation 
medicine injectors. Also, given the routine nature 
of data collection, significant goal data were missing; 
therefore, the strength of this analysis is reduced. 
Due to the large geographical area covered by this 
clinical service, patients receiving treatment are often 
reviewed and followed up by community teams, 
which has resulted in reduced goal and outcome data. 
Subsequent to the period covered in this study, further 
measures have been implemented, such as review 
by telephone and data collection by local teams, to 
improve capture of these data.
Thirdly, again due in part to the use of routinely 
collected data, there is a large disparity in the number 
of injections carried out per profession. While this is 
a finding in itself for the service evaluated, it results 
in limitations with the comparison, for example, in 
the range of muscles injected, as well as differences 
in goal classification per category for the professions.
CONCLUSIONS
In this study, comparable clinical outcomes 
between physiotherapy and rehabilitation medicine 
practitioners providing BoNT injections as 
intervention for spasticity have been identified. 
Some differences were seen in the muscles injected 
and the categories of goals set, but not in overall 
outcomes, as measured by the GAS T-score. No 
difference in side effect profile or the complexity 
of injections (e.g. complex clinical presentation, 
anticoagulation, or technical difficulty) was identified. 
In this cohort, injection of BoNT by a physiotherapist 
was as effective as that undertaken by a rehabilitation 
medicine physician in terms of the primary outcome 
of GAS. IJTR
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